Biology Reference
In-Depth Information
[30] Skert C, Damiani D, Michelutti A, Patriarca F, Arpinati M, Fili C, et al. Kinetics of Th1/
Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results
of a prospective study. Bone Marrow Transplant 2009;44:729-37.
[31] Tsoi MS, Storb R, Dobbs S, Medill L, Thomas ED. Cell-mediated immunity to non-HLA
antigens of the host by donor lymphocytes in patients with chronic graft-vs-host dis-
ease. J Immunol 1980;125:2258-62.
[32] Parkman R. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and
functional analysis of T lymphocyte clones. J Immunol 1986;136:3543-8.
[33] Sprent J, Kishimoto H. The thymus and central tolerance. Transplantation 2001;72:S25-8.
[34] Ghayur T, Seemayer TA, Xenocostas A, Lapp WS. Complete sequential regeneration of
graft-vs.-host-induced severely dysplastic thymuses: implications for the pathogenesis
of chronic graft-vs.-host disease. Am J Pathol 1988;133:39-46.
[35] Zhang Y, Hexner E, Frank D, Emerson SG. CD4+ T cells generated de novo from donor
hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host
disease. J Immunol 2007;179:3305-14.
[36] Morohashi T, Ogasawara K, Kitaichi N, Iwabuchi K, Onoe K. Abrogation of negative se-
lection by GVHR induced by minor histocompatibility antigens or H-2D antigen alone.
Immunobiology 2000;202:268-79.
[37] Akatsuka Y, Morishima Y, Kuzushima K, Kodera Y, Takahashi T. Minor histocompatibil-
ity antigens as targets for immunotherapy using allogeneic immune reactions. Cancer
Sci 2007;98:1139-46.
[38] Zorn E, Miklos DB, Floyd BH, Mattes-Ritz A, Guo L, Soiffer RJ, et al. Minor histocompat-
ibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell
transplantation. J Exp Med 2004;199:1133-42.
[39] Meadows L, Wang W, den Haan JM, Blokland E, Reinhardus C, Drijfhout JW, et al. The
HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine
that significantly affects T cell recognition. Immunity 1997;6:273-81.
[40] Vogt MH, Goulmy E, Kloosterboer FM, Blokland E, de Paus RA, Willemze R, et al. UTY
gene codes for an HLA-B60-restricted human male-specific minor histocompatibility
antigen involved in stem cell graft rejection: characterization of the critical polymor-
phic amino acid residues for T-cell recognition. Blood 2000;96:3126-32.
[41] Vogt MH, van den Muijsenberg JW, Goulmy E, Spierings E, Kluck P, Kester MG, et al.
The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocom-
patibility antigen involved in graft-versus-host disease. Blood 2002;99:3027-32.
[42] Spierings E, Vermeulen CJ, Vogt MH, Doerner LE, Falkenburg JH, Mutis T, et al. Identi-
fication of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper
cells in H-Y-mismatched transplantation. Lancet 2003;362:610-5.
[43] Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow
transplantation. Hematol Oncol Clin North Am 1990;4:687-98.
[44] Prentice HG, Blacklock HA, Janossy G, Bradstock KF, Skeggs D, Goldstein G, et al. Use
of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in
allogeneic bone-marrow transplantation for acute leukaemia. Lancet 1982;1:700-3.
[45] Waldmann H, Polliak A, Hale G, Or R, Cividalli G, Weiss L, et al. Elimination of graft-ver-
sus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal
rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984;2:483-6.
[46] de Witte T, Hoogenhout J, de Pauw B, Holdrinet R, Janssen J, Wessels J, et al. Deple-
tion of donor lymphocytes by counterflow centrifugation successfully prevents acute
graft-versus-host disease in matched allogeneic marrow transplantation. Blood
1986;67:1302-8.
[47] Wagner JE, Santos GW, Noga SJ, Rowley SD, Davis J, Vogelsang GB, et al. Bone marrow
graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical
trial. Blood 1990;75:1370-7.
[48] Slocombe GW, Newland AC, Yeatman NW, Macey M, Jones HM, Knott L. Allogeneic
bone marrow transplantation for adult leukaemia with soy bean lectin fractionated
marrow. Bone Marrow Transplant 1986;1:31-9.
[49] Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al.
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from
unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo
(GITMO). Blood 2001;98:2942-7.
[50] Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease pro-
phylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-
cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005;366:733-41.
[51] Pavletic SZ, Carter SL, Kernan NA, Henslee-Downey J, Mendizabal AM, Papadopou-
los E, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results
of a multicenter randomized trial in unrelated marrow donor transplantation. Blood
2005;106:3308-13.
320
Search WWH ::
Custom Search